슬롯사이트사이트 rate over twice that of existing immune checkpoint inhibitors… Technology evaluation complete by global ADC companies
[by Sung, Jae Jun] Y-Biologics, a biotechnology company specializing in anticancer 슬롯사이트사이트 drug development, announced on April 9 that it is accelerating the commercialization of its PD-L1 슬롯사이트사이트 candidates developed using its proprietary 슬롯사이트사이트 discovery platform.
Immune checkpoint inhibitors targeting PD-(L)1 have introduced significant advancements and innovations in cancer treatment. However, substantial unmet medical needs remain, as approximately 70% of all cancer patients exhibit resistance to these therapies. Notably, PD-L1 is highly expressed in a wide range of cancer types while exhibiting low expression in healthy tissues, making it an attractive target not only for immune checkpoint inhibitors but also for the development of 슬롯사이트사이트-drug conjugates (ADCs).
For the development ADCs, the cell internalization efficiency rate of the target 슬롯사이트사이트 is a critical factor. However, existing PD-L1 antibodies have faced limitations due to relatively low internalization rates. Y-Biologics address this challenge by leveraging its proprietary platform, Ymax-ABL, to identify a diverse array of PD-L1 antibodies. Through this approach, the company successfully secured candidate antibodies with an internalization rate more than twice as high as those of currently approved immune checkpoint inhibitors.
Furthermore, the company reported that, since the second half of last year, a global ADC-specialized company has been evaluating Y-Biologics’ PD-L1 candidate 슬롯사이트사이트 under a material transfer agreement (MTA) and has recently completed successfully.
"In addition to our PD-L1 슬롯사이트사이트 with a high internalization rate, we possess a meaningful portfolio of undisclosed 슬롯사이트사이트 candidates in the field of immuno-oncology," stated Park Young-woo, CEO of Y-Biologics. "We aim to deliver new treatment options by collaborating with global companies," he added.